Precigen Stock

Precigen EBIT

The EBIT of Precigen (PGEN) as of Jul 28, 2026 is -246.77 M USD. In the previous year, EBIT was -135.03 M USD — a change of 82.75% (lower).

EBIT

-246.77 MUSD

YoY

82.75%

Last updated:

In 2026, Precigen's EBIT was -246.77 M USD, a 82.75% increase from the -135.03 M USD EBIT recorded in the previous year.

The Precigen EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-99.76 base
Jan 1, 2024
-135.03 base
Jan 1, 2025
-246.77 base
Jan 1, 2026 (e)
-51.90 base
Jan 1, 2027 (e)
29.25 base
Jan 1, 2028 (e)
151.37 base
Jan 1, 2029 (e)
248.64 base
Jan 1, 2030 (e)
376.73 base
YEAREBIT (M USD)
2030 est 376.73
2029 est 248.64
2028 est 151.37
2027 est 29.25
2026 est -51.90
2025 -246.77
2024 -135.03
2023 -99.76
2022 -73.33
2021 -91.95
2020 -86.32
2019 -86.32
2018 -505.61
2017 -137.89
2016 -125.17
2015 -146.86
2014 -69.96
2013 -58.02
2012 -75.16
2011 -82.43
Access this data via the Eulerpool API

Precigen Revenue

Precigen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
6.23 M USD
-99.76 M USD
-95.90 M USD
Jan 1, 2024
3.93 M USD
-135.03 M USD
-126.24 M USD
Jan 1, 2025
9.68 M USD
-246.77 M USD
-250.64 M USD
Jan 1, 2026 (e)
124.43 M USD
-51.90 M USD
-10.61 M USD
Jan 1, 2027 (e)
229.02 M USD
29.25 M USD
70.76 M USD
Jan 1, 2028 (e)
413.74 M USD
151.37 M USD
256.24 M USD
Jan 1, 2029 (e)
523.05 M USD
248.64 M USD
321.20 M USD
Jan 1, 2030 (e)
618.08 M USD
376.73 M USD
335.63 M USD

Precigen Margins

Precigen stock margins

The Precigen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Precigen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Precigen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
1.70 %
-1,602.54 %
-1,540.63 %
Jan 1, 2024
-8.71 %
-3,440.23 %
-3,216.18 %
Jan 1, 2025
37.05 %
-2,548.24 %
-2,588.21 %
Jan 1, 2026 (e)
37.05 %
-41.71 %
-8.53 %
Jan 1, 2027 (e)
37.05 %
12.77 %
30.90 %
Jan 1, 2028 (e)
37.05 %
36.59 %
61.93 %
Jan 1, 2029 (e)
37.05 %
47.54 %
61.41 %
Jan 1, 2030 (e)
37.05 %
60.95 %
54.30 %

Precigen Stock analysis

What does Precigen do? Precigen Inc is a biotechnology company headquartered in Germantown, Maryland, USA. The company was founded in 1991 under the name Human Genome Sciences Inc and became the first company in the industry to unlock genetic genes for drug development. In 2019, the company was renamed Precigen Inc. The company specializes in the development of cell and gene therapy products based on the latest advances in regenerative medicine. The goal is to treat diseases that have been difficult or even considered incurable through gene therapy, genome sequencing, and artificial intelligence. Precigen is divided into several divisions: Precigen ActoBio, Precigen Genome, Precigen RegenX, and Precigen Triple Gem. The divisions differ in product development and target application areas. Precigen ActoBio focuses on the development of biological therapies for autoimmune diseases. The company is working on an oral immunotherapy that can treat respiratory and inflammatory bowel diseases. The product is in the testing phase and if all goes well, approval could be within reach. Precigen Genome specializes in genome sequencing. The data from the genes is decoded to develop better medical diagnoses and therapies. Precigen Genome's services range from sequencing genomic information to uncovering further details to interpreting genome data. Precigen RegenX develops gene therapy products for the treatment of rare but severe genetic diseases. The aim is to modify specific genes in the body to achieve a cure or alleviate symptoms. An example of a product from Precigen RegenX is a gene therapy for hemophilia. This product is being tested in phase II clinical trials and could represent a true revolution in treatment. Precigen Triple Gem is the company's newest division, founded in 2020. It is a research and development project focused on novel cancer therapies. The main focus is on the development of CAR-T cells that can recognize and destroy various types of cancer cells. The company has already achieved promising results. The products from Precigen aim to simplify the treatment of severe diseases and minimize side effects through integration into molecular medicine. Patient safety is the top priority. To ensure this, strict testing phases are undergone and there is close monitoring of product development. Precigen's business strategy is based on collaboration with other companies and institutions. The company works with large pharmaceutical companies to support production, distribution, and marketing of the products, among other partnerships. Another important partnership is with universities and research institutions, which help the company in developing new technologies, improving production processes, and conducting clinical trials. This collaboration leads to faster research insights and a larger pool of knowledge and know-how. Precigen is also committed to recruiting the best talent and qualified personnel in the field of biotechnology. Overall, Precigen is an extremely innovative and promising company in the field of regenerative medicine and gene therapy. The company relies on a clever business strategy and forward-thinking partnerships to develop even better therapies for serious, previously incurable diseases in the future. Precigen is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Precigen's EBIT

Precigen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Precigen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Precigen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Precigen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Precigen stock

EBIT of Precigen is -246.77 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Precigen

All Key Metrics — Precigen